HeartSciences (HSCS) Change in Accured Expenses (2021 - 2026)
HeartSciences (HSCS) posted quarterly Change in Accured Expenses of $220790.0 for Q2 2026, down 15.51% year-on-year from $261319.0 in Q2 2025, and up 166.06% on a QoQ basis from -$334208.0 in Q4 2025.
HeartSciences (HSCS) Change in Accured Expenses (2021 - 2026) Analysis & Trends
HeartSciences (HSCS) has reported Change in Accured Expenses for 6 consecutive years, with $220790.0 the latest figure, recorded in Q2 2026.
- Quarterly Change in Accured Expenses fell 15.51% year-over-year to $220790.0 in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $314619.0 (up 1773.74% YoY) and the FY2026 annual result came in at $121479.0, up 623.48% from the prior year.
- Change in Accured Expenses rose to $220790.0 in Q2 2026 per HSCS's latest filing, from -$334208.0 in the prior quarter.
- Over the last five years, Change in Accured Expenses for HSCS reached as high as $371484.0 in Q2 2022 and fell as low as -$477475.0 in Q3 2022.
- A 5-year average of $21705.2 and a median of $15744.0 in 2025 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses sank 997.02% — and 2025, when it jumped 472.92%.
- Year by year, Change in Accured Expenses stood at $247141.0 in 2022, then slumped by 126.67% to -$65901.0 in 2023, then sank by 227.11% to -$215566.0 in 2024, then tumbled by 55.04% to -$334208.0 in 2025, then soared by 166.06% to $220790.0 in 2026.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered $220790.0, -$334208.0, and $166718.0 for Q2 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | - |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | -654.00 Mn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 123.00 Mn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | -512.00 Mn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | -347.10 Mn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 145.10 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | -250.00 Mn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 21.07 Mn |
| 10 | HeartSciences | 6.43 Mn | 4.73 Mn | - | 220,790.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 220,790.00 |
| Apr 30, 2026 | 220,790.00 |
| Oct 31, 2025 | -334,208.00 |
| Oct 31, 2025 | -334,208.00 |
| Jul 31, 2025 | 166,718.00 |
| Jul 31, 2025 | 166,718.00 |
| Apr 30, 2025 | 261,319.00 |
| Apr 30, 2025 | 261,319.00 |
| Jan 31, 2025 | 15,744.00 |
| Jan 31, 2025 | 15,744.00 |
| Oct 31, 2024 | -215,566.00 |
| Oct 31, 2024 | -215,566.00 |
| Jul 31, 2024 | -44,706.00 |
| Jul 31, 2024 | -44,706.00 |
| Apr 30, 2024 | 82,718.00 |
| Apr 30, 2024 | 82,718.00 |
| Jan 31, 2024 | -103,237.00 |
| Jan 31, 2024 | -103,237.00 |
| Oct 31, 2023 | -65,901.00 |
| Oct 31, 2023 | -65,901.00 |